Novo Nordisk to invest $22M in North Carolina diabetes plant
- Novo Nordisk will invest $22 million in its Clayton, North Carolina manufacturing plant, creating 22 new jobs in the process, local government officials announced last week.
- Following this latest investment and another from earlier this year, the Johnson County board of commissioners has voted to approve a seven-year package of financial incentives for the Danish drugmaker.
- Novo has invested heavily in its Clayton facilities, most notably a near $2 billion expansion to expand production of active pharmaceutical ingredients for its diabetes medicines. More recently, the company said it would spend another $65 million on further build-out.
Since buying the site in 1991, Novo Nordisk has been making its mark on Clayton. Expansion has gathered speed in recent years.
In 2016, Novo put $1.8 billion into its diabetes active pharmaceutical ingredients plant, dubbed DAPI-US, which will produce a range of current and future diabetes and obesity medicines. This will employ 700 people once fully operational, set to occur in 2020.
This February, the company put $65 million into its diabetes finished products facility. That particular project is expected to complete in the fourth quarter of 2019, reaching full operation by 2020.
Novo Nordisk has also been involved in the $1.3 million remodeling of the Johnston County Workforce Development Center this year, and employs almost 1,200 manufacturing workers in the county.
"We take great pride in creating jobs and supporting economic growth in Johnston and neighboring counties in the Biopharma Crescent region," said Chad Henry, general manager of Novo's Diabetes Finished Products manufacturing site, in a statement.
- BioPharma Dive Novo earmarks $65M to expand NC production facility
Follow Suzanne Elvidge on Twitter